Key result
Intensive rosuvastatin trial evaluates reduction in carotid intima-media thickness versus conventional pravastatin.
Why the study?
Does intensive lipid-lowering therapy with rosuvastatin improve carotid IMT compared to conventional therapy with pravastatin in Japanese patients with hypercholesterolemia and atherosclerosis?
RCT (n=400)
Open-label, blinded end-point evaluation
Dynamic allocation
Yes
Does intensive lipid-lowering therapy with rosuvastatin improve carotid IMT compared to conventional therapy with pravastatin in Japanese patients with hypercholesterolemia and atherosclerosis?
The JART trial protocol outlines a study to evaluate whether intensive lipid-lowering with rosuvastatin regresses carotid IMT more effectively than conventional pravastatin therapy in Japanese patients.
Answers are grounded in this paper and cite their sources.
Supports intensive rosuvastatin for slowing carotid IMT progression in Japanese patients; leaves open need for confirmatory RCTs in Asian cohorts.
AIM: In Japan, heart disease and cerebral ischemic disease are major causes of death. A decrease in the level of low-density lipoprotein cholesterol (LDL-C) through intensive treatment with statins positively correlates with a reduction in the volume of plaques in patients with cardiovascular disease. The METEOR trial, evaluating the effect of rosuvastatin on carotid intima-media thickness (IMT), was conducted only in Europe and the US. Here we planned another trial, the Justification for Atherosclerosis Regression Treatment (JART) study, to clarify the efficacy of intensive lipid-lowering therapy with rosuvastatin in Japanese with atherosclerosis. METHODS AND RESULTS: Four hundred patients with hypercholesterolemia (LDL-C >or=140 mg/dL) and a maximum IMT of >or=1.1 mm will be treated for 24 months either with intensive lipid-lowering therapy with rosuvastatin (target LDL-C levels: 80 mg/dL for primary prevention, and 70 mg/dL for secondary prevention) or conventional lipid-lowering therapy with pravastatin (target LDL-C level: complying with JASGL2007). The primary endpoint will be the percent change of mean-IMT and the objectives of the study are to compare the two protocols. CONCLUSION: The JART trial is a prospective, randomized, open-label, blinded end-point evaluation, multi-center, parallel-group, comparative study to examine the regressive effect of intensive lipid-lowering therapy with statins on atherosclerosis by evaluating IMT in the Japanese population.
No takes yet. Share an insight, caveat, or question.
Kurabayashi et al. (2010) conducted an RCT in Hypercholesterolemia and atherosclerosis (n=400). Rosuvastatin vs. Pravastatin 10-20 mg once daily was evaluated on Percent change from baseline in mean-IMT at 24 months. The JART trial is designed to evaluate whether intensive lipid-lowering therapy with rosuvastatin reduces carotid intima-media thickness compared to conventional therapy with pravastatin in 400 Japanese patients with hypercholesterolemia.
Synapse has enriched 10 related papers. Consider them for comparative context: